These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32381868)

  • 21. Mutism and persistent dysarthria due to tacrolimus-based immunosuppression following allogeneic liver transplantation.
    Vearrier D; Simpson SE; Greenberg MI
    Am J Ther; 2011 Nov; 18(6):e274-6. PubMed ID: 20535006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2004; 43(10):623-53. PubMed ID: 15244495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient.
    Fukatsu S; Fukudo M; Masuda S; Yano I; Katsura T; Ogura Y; Oike F; Takada Y; Inui K
    Drug Metab Pharmacokinet; 2006 Apr; 21(2):122-5. PubMed ID: 16702731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic clearance improves after angioplasty of the hepatic vein.
    Narumi S; Hakamada K; Toyoki Y; Totsuka E; Niioka T; Umehara Y; Ono H; Nishimura A; Yoshihara S; Sasaki M
    Transplant Proc; 2004 Dec; 36(10):3091-2. PubMed ID: 15686702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late-onset acute rejection after living donor liver transplantation.
    Akamatsu N; Sugawara Y; Tamura S; Keneko J; Matsui Y; Hasegawa K; Makuuchi M
    World J Gastroenterol; 2006 Nov; 12(41):6674-7. PubMed ID: 17075982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation.
    Wu YJ; Lin YH; Yong CC; Li WF; Wang SH; Wang CC; Lin TL; Chen CL; Lin CC
    Ann Transplant; 2016 Jan; 21():30-4. PubMed ID: 26782179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.
    Jain A; Demetris AJ; Kashyap R; Blakomer K; Ruppert K; Khan A; Rohal S; Starzl TE; Fung JJ
    Liver Transpl; 2001 Jul; 7(7):623-30. PubMed ID: 11460230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
    Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
    Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leukoencephalopathy syndrome after living-donor liver transplantation.
    Umeda Y; Matsuda H; Sadamori H; Shinoura S; Yoshida R; Sato D; Utsumi M; Yagi T; Fujiwara T
    Exp Clin Transplant; 2011 Apr; 9(2):139-44. PubMed ID: 21453233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.
    Kato H; Usui M; Muraki Y; Tanemura A; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Okuda M; Nakatani K; Isaji S
    Transplant Proc; 2016 May; 48(4):1087-94. PubMed ID: 27320564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of deoxyschisandrin on blood tacrolimus levels: a case report.
    Jiang W; Wang X; Kong L
    Immunopharmacol Immunotoxicol; 2010 Mar; 32(1):177-8. PubMed ID: 19656076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper).
    Trotter JF; Wachs M; Bak T; Trouillot T; Stolpman N; Everson GT; Kam I
    Liver Transpl; 2001 Apr; 7(4):343-51. PubMed ID: 11303295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients.
    Jain A; Venkataramanan R; Sharma R; Kwong T; Orloff M; Abt P; Kashyap R; Tsoulfas G; Batzold P; Williamson M; Bozorgzadeh A
    Transplantation; 2008 Feb; 85(4):554-60. PubMed ID: 18347534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.